UCB SA (UCB)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account

Sell

€236.60

Buy

€236.80

arrow-down€-1.40 (-0.59%)

Prices updated at 16 Dec 2025, 14:48 CET

Prices minimum 15 mins delay

Prices in EUR

UCB SA is engaged in the development of novel therapies for the treatment of central nervous system and immunological diseases.

FTSE EuroFirst 300

-0.5%

Brussels

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Income statement

Year chevron-l-regular chevron-r-regular	2023	2024
	5,252m	6,152m
	3,545m	4,400m
	633m	864m
	12.05	14.04
	343m	1,065m
	1,276m	1,963m
Sales, General and administrative	1,824m	2,347m
Interest expenses	144m	159m
Provision for income taxes	98m	98m
Operating expenses	2,912m	3,536m
Income before taxes	441m	1,163m
Net income available to common shareholders	343m	1,065m
	1.81	5.61
Net interest income	-129m	-140m
Advertising and promotion	-	-
Net investment income, net	-54m	10m
Realised capital gains (losses), net	-	-
Total benefits, claims and expenses	-	-
Earnings per share (diluted)	1.76	5.48
Free cash flow per share	3.184	2.9132
Book value/share	47.6508	47.1105
Debt equity ratio	0.333816	0.295443

Balance sheet

Year chevron-l-regular chevron-r-regular	2023	2024
Current assets	3,444m	4,788m
Current liabilities	2,616m	3,529m
Total capital	11,853m	12,847m
Total debt	3,038m	3,026m
Total equity	8,975m	10,029m
Total non current liabilities	-	-
Loans	2,878m	2,818m
Total assets	15,539m	17,347m
Total liabilities	-	-
Cash and cash equivalents	861m	1,573m
Common stock	190m	190m

Cash flow

Year chevron-l-regular chevron-r-regular	2023	2024
Cash at beginning of period	859m	861m
Cash dividends paid	-252m	-259m
	445m	920m
Investments (gains) losses	-440m	282m
	861m	1,573m
Net income	-	-
	761m	1,242m
	-316m	-322m

The figures shown in the tables are quoted in the currency of the stock selected.

Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.